Transition from secukinumab to adalimumab in <scp>COVID‐19</scp>‐induced psoriasis flare‐up treatment: A case report-Reference-Cited by-同舟云学术

Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report

Published:2023-10 Issue:10 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Chen Yuting¹^ORCID,Qiu Yangyang¹,Chen Meiqing¹,Huang Ling¹,Lin Xinyu¹,Qiu Xiaoyan¹,Wei Yi¹²,Gao Lujuan¹²

Affiliation:

1. Department of Dermatology, Zhongshan Hospital (Xiamen) Fudan University Xiamen China

2. Department of Dermatology, Zhongshan Hospital Fudan University Shanghai China

Abstract

Key Clinical MessageCoronavirus disease 2019 (COVID‐19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune‐mediated dermatological diseases have been more extensively studied during the COVID‐19 pandemic. Herein, we report a case of flare‐up of previously well‐controlled psoriasis shortly after infection with COVID‐19, with treatment transition from secukinumab to adalimumab.

Funder

Natural Science Foundation of Fujian Province

Xiamen Municipal Bureau of Science and Technology

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.8047

Reference9 articles.

1. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis

2. Roles of Infection in Psoriasis

3. Psoriasis Flares in Patients With COVID-19 Infection or Vaccination: A Case Series

4. Biologics for Psoriasis During the COVID-19 Pandemic

5. New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secukinumab;Reactions Weekly;2023-12-02